Ebach, DR; Jester, TW; Galanko, JA; Firestine, AM; Ammoury, R; Cabrera, J; Bass, J; Minar, P; Olano, K; Margolis, P; Molle-Rios, Z; Saeed, SA; Bousvaros, A; Kappelman, MD. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2024; 119:1110-1116.

Allegretti, JR; Bordeianou, LG; Damas, OM; Eisenstein, S; Greywoode, R; Minar, P; Singh, S; Harmon, S; Lisansky, E; Malone-King, M; Litwin, NS; Weaver, A; Heller, CA; Moss, AC; Adler, J. Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases. 2024; 30:S55-S66.

Nasr, A; Mizuno, T; Irie, K; Dillman, J; Jackson, K; Lynch, K; Horrell, A; Chun, KY; Yang, JM; Hyams, JS; Boyle, BM; Noe, JD; Denson, LA; Minar, PP. 958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE. Gastroenterology. 2024; 166:s-226-s-227.

Minar, PP; Karns, R; Lynch, K; Jackson, K; Horrell, A; Boyle, BM; Hyams, JS; Noe, JD; Denson, LA. 748 EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE. Gastroenterology. 2024; 166:s-177-s-178.

Minar, PP; Colman, RJ; Zhang, N; Mizuno, T; Vinks, AA. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 2024; 14:e077193.

Dike, CR; Ollberding, NJ; Thompson, T; Kotha, N; Minar, P; Vitale, DS; Lin, TK; Nasr, A; Denson, LA; Haslam, DB; Abu-El-Haija, M. Acute pancreatitis is associated with gut dysbiosis in children. Digestive and Liver Disease. 2024; 56:444-450.

Romo, MV; Acharya, K; Shelman, NR; Minar, P; Denson, LA; Softic, S. De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics. 2024; 8:1-4.

Samuels, A; Whaley, KG; Minar, P. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports. 2023; 25:323-332.

Dike, C; Ollberding, N; Thompson, T; Kotha, N; Minar, P; Vitale, D; Lin, T; Nasr, A; Denson, L; Haslam, D; Abu-El-Haija, M. Acute pancreatitis is associated with gut dysbiosis in children. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2023; 23:e3-e4.

Nasr, A; Minar, P. The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America. 2023; 52:549-563.

Smith, J; Liu, C; Beck, A; Fei, L; Brokamp, C; Meryum, S; Whaley, KG; Minar, P; Hellmann, J; Denson, LA; Margolis, P; Dhaliwal, J. Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White Children. The Journal of Pediatrics. 2023; 260:113522.

Colman, RJ; Samuels, A; Mizuno, T; Punt, N; Vinks, AA; Minar, P. Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023; 29:1342-1346.

Kappelman, MD; Wohl, DA; Herfarth, HH; Firestine, AM; Adler, J; Ammoury, RF; Aronow, JE; Bass, DM; Bass, JA; Benkov, K; Zikry, M; Weinberger, M; Saeed, SA; Bousvaros, A. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023; 165:149-161.e7.

Khandelwal, P; Lounder, DT; Bartlett, A; Haberman, Y; Jegga, AG; Ghandikota, S; Koo, J; Luebbering, N; Leino, D; Abdullah, S; Karns, R; Nelson, AS; Denson, LA; Davies, SM. Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease. Haematologica: the hematology journal. 2023; 108:1803-1816.

Dike, C; Ollberding, N; Thompson, T; Kotha, N; Minar, PP; Vitale, DS; Lin, TK; Nasr, A; Denson, LA; Haslam, D; Abu-El-Haija, M. Su1884 ACUTE PANCREATITIS IS ASSOCIATED WITH GUT DYSBIOSIS IN CHILDREN. Gastroenterology. 2023; 164:s-703.

Smith, J; Howard, CA; Etter, R; Hellmann, J; Whaley, KG; Minar, PP; Denson, LA; Margolis, P; Dhaliwal, J. Su1013 EVALUATION OF INSURANCE TYPE ON PRIOR AUTHORIZATION (PA) DELAYS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS PRESCRIBED BIOLOGIC THERAPIES. Gastroenterology. 2023; 164:s-504-s-505.

Adler, J; Tribble, AC; Boyle, BM; Chavannes, M; Egberg, MD; Frischer, JS; Gayer, C; Kandavel, P; Kim, SC; McMahon, L; Nwomeh, B; Pasternak, B; Phillips, MR; Gadepalli, S. 860 ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN'S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP. Gastroenterology. 2023; 164:s-188.

Gadepalli, S; Boyle, BM; Chavannes, M; Egberg, MD; Frischer, JS; Gayer, C; Kandavel, P; Kim, SC; McMahon, L; Minar, PP; Mollen, K; Nwomeh, B; Pasternak, B; Phillips, MR; Adler, J. 513 DISPARITIES IN OSTOMY CREATION FOR PERIANAL FISTULIZING COMPLICATIONS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE WITHIN A MULTI-INSTITUTIONAL COHORT. Gastroenterology. 2023; 164:s-1477.

Samuels, A; Punt, N; Mizuno, T; Vinks, AA; Minar, PP. 347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS. Gastroenterology. 2023; 164:s-59.

Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; D'Haens, GR; Denson, LA; Vinks, AA; Rosen, MJ. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023; 21:1338-1347.

Colman, RJ; Mizuno, T; Fukushima, K; Haslam, DB; Hyams, JS; Boyle, B; Noe, JD; D'Haens, GR; Van Limbergen, J; Chun, K; Yang, J; Denson, LA; Ollberding, NJ; Vinks, AA; Minar, P. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary Pharmacology and Therapeutics. 2023; 57:524-539.

Colman, RJ; Minar, P. Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply. Alimentary Pharmacology and Therapeutics. 2023; 57:567-568.

Colman, RJ; Dykes, DM H; Arce-Clachar, AC; Saeed, SA; Minar, P. Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. Pediatric Inflammatory Bowel Disease. : Springer Nature; Springer Nature; 2023.

Matula, KA; Minar, P; Daraiseh, NM; Lin, L; Recker, M; Lipstein, EA. Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Health Expectations. 2022; 25:3105-3113.

Clarkston, K; Karns, R; Jegga, AG; Sharma, M; Fox, S; Ojo, BA; Minar, P; Walters, TD; Griffiths, AM; Mack, DR; Haberman, Y; Hyams, JS; Denson, LA; Rosen, MJ. Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis. Journal of Crohn's and Colitis. 2022; 16:1735-1750.

Daraiseh, NM; Black, A; Minar, P; Meisman, A; Saxe, M; Lipstein, EA. iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis. Patient Education and Counseling. 2022; 105:1628-1633.

Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; Rosen, MJ; Denson, LA; Vinks, A; Minar, P. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

Miller, TL; Schuchard, J; Carle, AC; Forrest, CB; Kappelman, MD; Adler, J; Ammoury, RF; Bass, D; Bass, J; Benkov, K; Strople, J; Sullivan, JS; Tung, J; Wali, P. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn's Disease. The Journal of Pediatrics. 2022; 242:86-92.e3.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Gastroenterology. 2022; 162:s98-s99.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Gastroenterology. 2022; 162:s99-s100.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Gastroenterology. 2022; 162:s100.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Inflammatory Bowel Diseases. 2022; 28:s99-s100.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Inflammatory Bowel Diseases. 2022; 28:s100.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Inflammatory Bowel Diseases. 2022; 28:s98-s99.

Colman, RJ; Tsai, YT; Jackson, K; Boyle, BM; Noe, JD; Hyams, JS; D'Haens, GR A M; Van Limbergen, J; Rosen, MJ; Denson, LA; Minar, P. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflammatory Bowel Diseases. 2021; 27:1045-1051.

Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; Rosen, MJ; Denson, LA; Vinks, AA; Minar, P. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.

Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ. Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Pediatric Quality and Safety. 2021; 6:e400.

Minar, PP; Jegga, A; Ghandikota, S; Karns, R; Hyams, JS; Noe, JD; Boyle, BM; Rosen, MJ; Denson, LA. 728 PLASMA PROTEOMIC RESPONSE SIGNATURE FOR CHILDREN RECEIVING INFLIXIMAB FOR CROHN'S DISEASE. Gastroenterology. 2021; 160:s-145-s-146.

Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, JR; Leleiko, NS; Shapiro, JM; Denson, LA; D'Haens, GR; Vinks, AA; Rosen, MJ. 727 ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Gastroenterology. 2021; 160:s-145.

Colman, RJ; Portocarrero-Castillo, A; Chona, D; Hellmann, J; Minar, P; Rosen, MJ. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory Bowel Diseases. 2021; 27:507-515.

Lyles, JL; Mulgund, AA; Bauman, LE; Su, W; Fei, L; Chona, DL; Sharma, P; Etter, RK; Hellmann, J; Denson, LA; Minar, P; Dykes, DM; Rosen, MJ. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2021; 27:482-492.

Whaley, K; Xiong, V; Karns, R; Hyams, J; Kugathasan, S; Boyle, B; Walters, T; Kelsen, J; LeLeiko, N; Shapiro, J; Denson, L; D’Haens, G; Vinks, A; Rosen, M. ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Gastroenterology. 2021; 160:s75-s76.

Haberman, Y; Minar, P; Karns, R; Dexheimer, PJ; Ghandikota, S; Tegge, S; Shapiro, D; Shuler, B; Venkateswaran, S; Braun, T; Hyams, JS; Kugathasan, S; Jegga, AG; Denson, LA. Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's Disease. Journal of Crohn's and Colitis. 2021; 15:273-286.

Whaley, K; Xiong, V; Karns, R; Hyams, J; Kugathasan, S; Boyle, B; Walters, T; Kelsen, J; LeLeiko, N; Shapiro, J; Denson, L; D’Haens, G; Vinks, A; Rosen, M. ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Inflammatory Bowel Diseases. 2021; 27:s55-s56.

Plevinsky, JM; Denson, LA; Hellmann, J; Minar, P; Rosen, MJ; Hommel, KA. A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology and Nutrition. 2020; 71:366-370.

Meisman, A; Daraiseh, NM; Minar, P; Saxe, M; Lipstein, EA. The Gray Zone: Adolescent and Young Adult Decision Support Needs for Ulcerative Colitis. MDM Policy and Practice. 2020; 5:2381468320940708.

Minar, PP; Xiong, Y; Mizuno, T; Colman, RJ; Hyams, JS; Noe, JD; Boyle, BM; Chun, KY; Yang, JM; Tsai, YT; Jackson, K; Rosen, MJ; Denson, LA; Vinks, AA. 1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE. Gastroenterology. 2020; 158:s-233-s-234.

Colman, RJ; Mizuno, T; Meryum, S; Vinks, AA; Minar, PP. Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. Gastroenterology. 2020; 158:s-967-s-968.

Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, BM; Chun, KY; Yang, JM; Rosen, MJ; Denson, LA; Vinks, AA; Minar, PP. 613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. Gastroenterology. 2020; 158:s-130-s-131.

Haberman, Y; Minar, PP; Karns, R; Dexheimer, PJ; Ghandikota, S; Tegge, S; Shapiro, D; Shuler, B; Venkateswaran, S; Braun, T; Hyams, JS; Kugathasan, S; Jegga, A; Denson, LA. 935 PRE-TREATMENT MUCOSAL INFLAMMATORY AND WOUND HEALING GENE PROGRAMS REVEAL MECHANISMS ASSOCIATED WITH FUTURE STRICTURING BEHAVIOR DURING FIVE YEAR FOLLOW-UP IN PEDIATRIC CROHN'S DISEASE. Gastroenterology. 2020; 158:s-187-s-188.

Bauman, LE; Xiong, Y; Mizuno, T; Minar, P; Fukuda, T; Dong, M; Rosen, MJ; Vinks, AA. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2020; 26:429-439.

Colman, R; Boyle, B; Noe, J; Hyams, J; Minar, P. 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD). Gastroenterology. 2020; 158:s112.

Colman, R; Boyle, B; Noe, J; Hyams, J; Minar, P. 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD). Inflammatory Bowel Diseases. 2020; 26:s68-s69.

Haberman Ziv, Y; Minar, P; Karns, R; Dexheimer, P; Ghandikota, S; Tegge, S; Shapiro, D; Shuler, B; Venkateswaran, S; Braun, T; Hyams, J; Kugathasan, S; Jegga, A; Denson, L. DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease. Journal of Crohn's and Colitis. 2020; 14:s127.